AVANIR (AVNR) Higher After Zenvia Met Primary Endpoint
More News related to AVNR
- AVANIR Pharma (AVNR) Files $75M Mixed Shelf
- AVANIR Pharmaceuticals Announces Fiscal 2010 Third Quarter Financial Results
- AVANIR to Present at the Canaccord Genuity Growth Conference
- AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
- AVANIR to Present at the Wedbush Life Sciences Conference
More News related to FDA
- Cerus (CERS) Announces Successful Completion of INTERCEPT-Treated Trial
- Seattle Genetics (SGEN) Achieves Milestone in Agensys Collaboration
- Halozyme Therapeutics (HALO) Initiates Two Phase IIs for rHuPH20
- Oncolytics Biotech (ONCY) Announces the GOG Will Initiate REOLYSIN Phase II
- Orexigen Therapeutics and Takeda Partner Up for Contrave Development
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is surging higher in pre-open trading after the comapny announced that the investigational drug Zenvia met its primary efficacy endpoint in the treatment of pseudobulbar affect (PBA) in the confirmatory Phase III STAR trial.
Both Zenvia 30/10 mg and 20/10 mg provided a statistically significant reduction in episode rates over the course of the study when compared to placebo (p<0.0001). In an additional analysis of the primary endpoint, at week twelve (end of study), patients in the Zenvia 30/10 mg group reported a statistically significant mean reduction of 88% from baseline in PBA episode rates (p=0.01). Also in this study, Zenvia was generally safe and well tolerated.
Create E-mail AlertRelated Categories
FDAMomentum Movers
Stocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
